0001017110false--12-31Q220220.00130000000024071255285712550.00120000000000679092545005450013000340833193533331930000000200000000.0010.00126038572026038572260385720000010171102022-01-012022-06-300001017110srt:DirectorMemberus-gaap:SubsequentEventMember2022-07-090001017110srt:ChiefExecutiveOfficerMember2022-01-012022-06-300001017110srt:ChiefFinancialOfficerMember2022-01-012022-06-300001017110gthr:PreferredStockSeriesBMember2022-06-300001017110gthr:PreferredStockSeriesBMember2021-12-3100010171102021-03-172021-03-180001017110gthr:PreferredStocksSeriesAMember2022-01-012022-06-300001017110srt:MaximumMember2022-06-300001017110srt:MinimumMember2022-06-300001017110gthr:TransferAgentsMember2021-01-012021-06-300001017110gthr:TransferAgentsMember2021-05-012021-05-090001017110gthr:TransferAgentsMember2022-01-012022-06-300001017110gthr:TransferAgentsMember2021-05-090001017110srt:ChiefOperatingOfficerMember2021-12-310001017110srt:ChiefOperatingOfficerMember2022-06-3000010171102021-05-012021-05-090001017110gthr:PreferredStocksSeriesAMember2022-06-300001017110gthr:PreferredStocksSeriesAMember2021-12-310001017110us-gaap:RetainedEarningsMember2022-04-012022-06-300001017110gthr:StockToBeIssuedMember2022-04-012022-06-300001017110us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001017110us-gaap:CommonStockMember2022-04-012022-06-3000010171102022-03-310001017110us-gaap:RetainedEarningsMember2022-03-310001017110gthr:StockToBeIssuedMember2022-03-310001017110us-gaap:AdditionalPaidInCapitalMember2022-03-310001017110us-gaap:CommonStockMember2022-03-310001017110gthr:SeriesBPreferredStocksMember2022-03-310001017110us-gaap:RetainedEarningsMember2022-06-300001017110gthr:StockToBeIssuedMember2022-06-300001017110us-gaap:AdditionalPaidInCapitalMember2022-06-300001017110us-gaap:CommonStockMember2022-06-300001017110gthr:SeriesBPreferredStocksMember2022-06-300001017110us-gaap:RetainedEarningsMember2022-01-012022-06-300001017110gthr:StockToBeIssuedMember2022-01-012022-06-300001017110us-gaap:AdditionalPaidInCapitalMember2022-01-012022-06-300001017110us-gaap:CommonStockMember2022-01-012022-06-300001017110gthr:SeriesBPreferredStocksMember2022-01-012022-06-300001017110us-gaap:RetainedEarningsMember2021-12-310001017110gthr:StockToBeIssuedMember2021-12-310001017110us-gaap:AdditionalPaidInCapitalMember2021-12-310001017110us-gaap:CommonStockMember2021-12-310001017110gthr:SeriesBPreferredStocksMember2021-12-310001017110us-gaap:RetainedEarningsMember2021-04-012021-06-300001017110us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001017110us-gaap:CommonStockMember2021-04-012021-06-3000010171102021-03-310001017110us-gaap:RetainedEarningsMember2021-03-310001017110gthr:StockToBeIssuedMember2021-03-310001017110us-gaap:AdditionalPaidInCapitalMember2021-03-310001017110us-gaap:CommonStockMember2021-03-310001017110gthr:SeriesBPreferredStocksMember2021-03-3100010171102021-06-300001017110us-gaap:RetainedEarningsMember2021-06-300001017110gthr:StockToBeIssuedMember2021-06-300001017110us-gaap:AdditionalPaidInCapitalMember2021-06-300001017110us-gaap:CommonStockMember2021-06-300001017110gthr:SeriesBPreferredStocksMember2021-06-300001017110us-gaap:RetainedEarningsMember2021-01-012021-06-300001017110us-gaap:AdditionalPaidInCapitalMember2021-01-012021-06-300001017110us-gaap:CommonStockMember2021-01-012021-06-3000010171102020-12-310001017110us-gaap:RetainedEarningsMember2020-12-310001017110gthr:StockToBeIssuedMember2020-12-310001017110us-gaap:AdditionalPaidInCapitalMember2020-12-310001017110us-gaap:CommonStockMember2020-12-310001017110gthr:SeriesBPreferredStocksMember2020-12-3100010171102021-01-012021-06-3000010171102021-04-012021-06-3000010171102022-04-012022-06-300001017110us-gaap:SeriesBPreferredStockMember2021-12-310001017110us-gaap:SeriesBPreferredStockMember2022-06-300001017110us-gaap:SeriesAPreferredStockMember2021-12-310001017110us-gaap:SeriesAPreferredStockMember2022-06-3000010171102021-12-3100010171102022-06-3000010171102022-08-17iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:pure

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended June 30, 2022

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM ______ TO _________

Commission File Number:

000-27237

GeneThera, Inc.

(Exact name of registrant as Specified in its Charter)

Nevada		65-0622463
(State or Other Jurisdiction of		(Internal Revenue Service
Incorporation or Organization)		Employer Identification Number)

3051 W. 105th Ave. #350251, Westminster, CO		80035
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code:

(720) 587-5100

Securities registered pursuant to Section 12(b) of the Exchange Act:

None

Securities registered pursuant to Section 12(g) of the Exchange Act:

Common Stock, $0.001 par value

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, and accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated Filer	☐	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act. Yes ☐ No ☒

State the number of shares of the issuer’s common stock outstanding, as of the latest practicable date: 35,333,319 shares of common stock issued and outstanding as of August 17, 2022.

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements.

GeneThera, Inc.

June 30, 2022

Index to the Condensed Consolidated Financial Statements

Condensed Consolidated Balance Sheets as of June 30, 2022 (Unaudited) and December 31, 2021		3

Condensed Consolidated Statements of Operations for the Three and Six Months ended June 30, 2022 and 2021 (unaudited)		4

Condensed Consolidated Statements of Stockholder’s Deficit for the Three and Six Months Ended June 30, 2022 and 2021 (unaudited)		5

Condensed Consolidated Statements of Cash Flows for the Six Months ended June 30, 2022 and 2021 (unaudited)		6

Notes to the Condensed Consolidated Financial Statements (unaudited)		7

Table of Contents

GeneThera, Inc.

Condensed Consolidated Balance Sheets

	June 30, 2022			December 31, 2021
	(unaudited)
ASSETS
Current assets
Cash	$	-		$	-
Prepaid expenses		-			1,022
Total current assets		-			1,022
Property and equipment
Automobile & Trucks		26,400			26,400
Less: Accumulated depreciation		(23,760	)		(21,120	)
Total property and equipment, net		2,640			5,280
Other assets		-			-
TOTAL ASSETS	$	2,640		$	6,302

LIABILITIES & STOCKHOLDERS’ DEFICIT
Current liabilities
Accounts payable	$	91,070		$	81,070
Accrued expenses		7,520,573			7,286,651
Notes payable		25,800			25,800
Convertible notes payable, net of discount		64,500			64,500
Loan from shareholder		716,569			720,969
Total liabilities		8,418,512			8,178,990

Commitments and Contingencies		-			-

Stockholders’ deficit:
Series A preferred stock, par value $0.001 per share, 20,000,000 shares authorized, 0 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively		-			-
Series B preferred stock, par value $0.001 per share, 30,000,000 shares authorized, 26,038,572 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively		26,039			26,039
Common stock, par value $0.001 per share, 300,000,000 shares authorized, 28,571,255 and 24,071,255 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively		35,333			34,083
Common stock to be issued		53,572			53,572
Additional paid-in capital		24,021,313			23,985,064
Accumulated deficit		(32,552,129	)		(32,271,446	)
Total stockholders’ deficit		(8,415,872	)		(8,172,688	)
TOTAL LIABILITIES & STOCKHOLDERS’ DEFICIT	$	2,640		$	6,302

See accompanying notes to unaudited condensed consolidated financial statements.

Table of Contents

GeneThera, Inc.

Condensed Consolidated Statements of Operations

(unaudited)

	Three Months Ended						Six Months Ended
	June 30,						June 30
	2022			2021			2022			2021

Expenses
General and administrative expenses	$	29,562		$	166,906		$	43,931		$	253,681
Payroll expenses		116,500			116,500			233,000			233,000
Depreciation		1,320			1,320			2,640			2,640
Total operating expenses		147,382			284,726			279,571			489,321
Loss from operations		(147,382	)		(284,726	)		(279,571	)		(489,321	)

Other expenses		(556	)		(1,646	)		(1,112	)		(3,292	)
Interest expense		-			-			-			-
Total other expense		(556	)		(1,646	)		(1,112	)		(3,292	)

Other Income		-			-			-			-
Total other Income		-			-			-			-
Net loss before income taxes		(147,938	)		(286,372	)		(280,683	)		(492,613	)
Provision for income taxes		-			-			-			-
Net loss	$	(147,938	)	$	(286,372	)	$	(280,683	)	$	(492,613	)
Loss per common share - Basic and diluted	$	(0.00	)	$	(0.01	)	$	(0.01	)	$	(0.02	)
Weighted average common shares outstanding - Basic and diluted		34,203,481			24,104,588			34,113,858			24,829,132

See accompanying notes to unaudited condensed consolidated financial statements.

Table of Contents

GeneThera, Inc.

Statements of Stockholders’ Deficit

June 30, 2022

(unaudited)

For the Three Months Ended June 30, 2022 and 2021

	Series B								Additional							Total
	Preferred Stock				Common Stock				Paid-in		Stock to		Accumulated			Stockholders’
	Shares		Amount		Shares		Amount		Capital		be issued		Deficit			Deficit

Balance at March 31, 2021		26,038,572	$	26,039		25,571,255	$	25,571	$	23,529,776	$	53,572	$	(31,466,203	)	$	(7,831,245	)

Shares issued for advisory						3,000,000		3,000		177,000							180,000
Net loss														(286,372	)		(286,372	)

Balance at June 30, 2021		26,038,572	$	26,039		28,571,255	$	28,571	$	23,706,776	$	53,572	$	(31,752,575	)	$	(7,937,617	)

Balance at March 31, 2022		26,038,572	$	26,039		34,083,319	$	34,083	$	23,985,064	$	53,572	$	(32,404,191	)	$	(8,305,433	)
Shares issued for services						816,667		817		23,683		-		-			24,500
Shares issued for convertible notes						433,333		433		12,567		-		-			13,000

Net loss														(147,938	)		(147,938	)

Balance at June 30, 2022		26,038,572	$	26,039		35,333,319	$	35,333	$	24,021,314	$	53,572	$	(32,552,129	)	$	(8,415,871	)

Six Months ended June 30, 2021

Balance at December 31, 2020		26,038,572	$	26,039		24,071,255	$	24,071	$	23,475,776	$	53,572	$	(31,259,962	)	$	(7,680,504	)

Shares issued for advisory						4,500,000		4,500		231,000							235,500
Net loss														(492,613	)		(492,613	)
Balance at June 30, 2021		26,038,572	$	26,039		28,571,255	$	28,571	$	23,706,776	$	53,572	$	(31,752,575	)	$	(7,937,617	)

Six Months ended June 30, 2022

Balance at December 31, 2021		26,038,572	$	26,039		34,083,319	$	34,083	$	23,985,064	$	53,572	$	(32,271,446	)	$	(8,172,688	)
Shares issued for services		-		-		816,667		817		23,683		-		-			24,500
Shares issued for convertible notes		-		-		433,333		433		12,567		-		-			13,000
Net loss								-		-		-		(293,683	)		(293,683	)

Balance at June 30, 2022		26,038,572	$	26,039		35,333,319	$	35,333	$	24,021,314	$	53,572	$	(32,552,129	)	$	(8,415,871	)

See accompanying notes to the unaudited condensed consolidated financial statements.

Table of Contents

GeneThera, Inc.

Condensed Consolidated Statements of Cash Flows

	For the Six Months Ended
	June 30,
	2022			2021
	(unaudited)			(unaudited)
Cash flows from operating activities
Net loss	$	(280,683	)	$	(492,613	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		-			-
Depreciation and amortization		2,640			2,640
Shares issued for services		24,500			235,500
Changes in operating assets and liabilities:
Prepaid Expenses		1,022			-
Deposits		-			-
Accounts payable and accrued expenses - related parties		-			-
Accounts payable and accrued expenses		243,921			235,801
Net cash used in operating activities		(8,600	)		1,328

Cash flows from investing activities
Purchase of Fixed Asset		-			-
Net cash used in investing activities		-			-
Cash flows from financing activities
Proceeds from convertible notes		13,000			-
Increase (decrease) in loans to shareholders		(4,400	)		(1,328	)
Net cash provided by financing activities		8,600			(1,328	)

Net decrease in cash		-			-
Cash at the beginning of the year		-			-
Cash at the end of the year	$	-		$	-

Cash paid for interest	$	-		$	-
Cash paid for income taxes	$	-		$	-

See accompanying notes to unaudited condensed consolidated financial statements.

Table of Contents

GENETHERA, INC.

June 30, 2022

Notes to the Condensed Consolidated Financial Statements

(Unaudited)

Note 1 – Organization and nature of operations and summary of significant accounting policies

Organization and nature of operations

The consolidated financial statements include GeneThera, Inc. and its wholly owned subsidiary GeneThera, Inc. (Colorado) (collectively, the “Company”). The Company had a long-standing research collaboration with GTI Research.

The Company is a biotechnology company that develops molecular assays and therapeutics for the detection and treatment for COVID-19 and other zoonotic diseases.

Basis of Presentation – Unaudited Financial Information

The accompanying unaudited condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the “SEC”) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited condensed consolidated financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements of the Company for the year ended December 31, 2021 and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC.

Use of estimates

The preparation of financial statements in accordance with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Certain prior period amounts in the consolidated financial statements and accompanying notes have been reclassified to conform to the current period’s presentation.

Principles of consolidation

The consolidated financial statements include the accounts of the Company and its subsidiary. All intercompany accounts are eliminated upon consolidation.

Cash and cash equivalents

Cash equivalents are highly liquid investments with an original maturity of three months or less.

Fair Value of Financial Instruments

For purpose of this disclosure, the fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced sale or liquidation. The carrying amount of the Company’s short-term financial instruments approximates fair value due to the relatively short period to maturity for these instruments.

Property and equipment, net

Property and equipment consist primarily of office and laboratory equipment, leasehold improvements, vehicle, and is stated at cost. Depreciation is computed on a straight-line basis over the estimated useful lives ranging from five to seven years. Leasehold improvements are amortized over the shorter of their economic lives or lease terms.

Table of Contents

Fair Value of Financial Instruments

The Company follows ASC 820-10 of the FASB Accounting Standards Codification to measure the fair value of its financial instruments and disclosures about fair value of its financial instruments. ASC 820-10 establishes a framework for measuring fair value in accounting principles generally accepted in the United States of America (U.S. GAAP) and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820-10 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The three (3) levels of fair value hierarchy defined by ASC 820-10 are described below:

Level 1	Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.

Level 2	Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.

Level 3	Pricing inputs that are generally unobservable inputs and not corroborated by market data.

Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable.

The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

The carrying amounts of the Company’s financial assets and liabilities, such as cash, accounts receivable, inventory, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values because of the short maturity of these instruments.

Transactions involving related parties typically cannot be presumed to be carried out on an arm’s-length basis, as the requisite conditions of competitive, free-market dealings may not exist.

Reclassifications

Certain prior period amounts may have been reclassified to conform to current period presentation.

Impairment of Long-Lived Assets

The Company reviews the recoverability of its long-lived assets to determine whether events or changes in circumstances occurred that indicate the carrying value of the asset may not be recoverable. The assessment of possible impairment is based on the ability to recover the carrying value of the asset from the expected future cash flows of the related operations. If these cash flows are less than the carrying value of such asset, an impairment loss is recognized for the difference between the estimated fair value and carrying value. The measurement of impairment requires management to make estimates of these cash flows related to long-lived assets, as well as other fair value determinations.

Revenue recognition

There were no revenues during the six months ended June 30, 2022 and 2021, respectively.

The Company follows the FASB Accounting Standards Codification ASC 606 – Revenues from Contracts with Customers for revenue recognition. The Company considers revenue realized or realizable and earned when all the following criteria are met:

1)	Identification of the contract with a customer;

2)	Identification of the performance obligations in the contract;

3)	Determination of the transaction price;

4)	Allocation of the transaction price to the performance obligations in the contract; and

Recognition of revenue when or as a performance obligation is satisfied. Revenue is recognized when each performance obligation is satisfied by the entity. An estimate of the variable consideration or performance obligations that an entity ultimately expects to be entitled to is included in the transaction price, and revenue is recognized upon satisfaction of the related performance obligation(s). An implicit or explicit significant financing component is taken into consideration. IP licenses must be analyzed. Each contract with customers is analyzed for multiple elements if any element must stand alone.

Table of Contents

Stock-Based Compensation

Stock-based compensation is accounted for under FASB ASC Topic No. 718 – Compensation – Stock Compensation. The guidance requires recognition in the financial statements of the cost of employee services received in exchange for an award of equity instruments over the period the employee is required to perform the services in exchange for the award (presumptively the vesting period). The guidance also requires measurement of the cost of employee services received in exchange for an award based on the grant-date fair value of the award. The Company accounts for non-employee share-based awards in accordance with guidance related to equity instruments that are issued to other than employees for acquisition, or in conjunction with selling, goods or services.

Income taxes

Income taxes are accounted for in accordance with the provisions of FASB ASC Topic No. 740 - Income Taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amounts expected to be realized.

Table of Contents

Basic and diluted net loss per common share

Basic and diluted net loss per share calculations are presented in accordance with FASB ASC Topic No. 260 – Earnings per Share and are calculated on the basis of the weighted average number of common shares outstanding during the period. Diluted per share calculations includes the dilutive effect of common stock equivalents in years with net income. As the Company is in a loss position, any calculation of the dilutive effects of the Company’s convertible securities would reduce the loss per share amount, and, as such, the Company will not perform the calculation.

Recently issued accounting pronouncements

Management has evaluated all recent accounting pronouncements as issued by the FASB in the form of Accounting Standards Updates (“ASU”) through the date these financial statements were available to be issued and found no recent accounting pronouncements issued, but not yet effective accounting pronouncements, when adopted, will have a material impact on the financial statements of the Company.

Note 2- Going Concern

As reflected in the accompanying consolidated financial statements, the Company has an accumulated deficit of $32,552,129 and negative working capital of $8,418,512 as of June 30, 2022. This raises substantial doubt about the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern is dependent on its ability to raise additional capital and implement its business plan. The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Management believes that actions presently being taken to obtain additional funding and implement its strategic plans provide the opportunity for the Company to continue as a going concern.

Presently, the Company is considering ways to apply its molecular robotic technology to address the COVID-19 pandemic. Management believes that actions presently being taken to obtain additional funding and implement its strategic plans provide the opportunity for the Company to continue as a going concern.

Note 3 – Property and Equipment

As of June 30, 2022, the Company had a vehicle with a net book value of $2,640.

Table of Contents

Note 4 – Related party transactions

The Company has an outstanding loan payable and accrued interest to Antonio Milici, its CEO and stockholder amounting to $679,092 as of June 30, 2022 and December 31, 2021, respectively. This outstanding loan to the Company is unsecured and bears interest at 2.41%. The Company has an outstanding loan and accrued interest payable to Tannya Irizarry, its interim CFO interim and stockholder, amounting to $43,477 and $58,704 as of June 30, 2022 and December 31, 2021, respectively. This outstanding loan to the Company is unsecured and bears interest at 8%.

Tannya Irizarry owns 50% of GTI Corporate Transfer Agents, LLC, and the Company’s transfer agency. During the six months ended June 30, 2022 and 2021, the Company made payments to GTI Corporate Transfer Agents, LLC in the amounts of $1,700 and $80, respectively.

During the three months ended June 30, 2022, the Company:

	·	issued 816,667 shares of common stock to a director who joined the Board of Directors in the same time frame for services and recognized an expense of $24,500;
	·	issued 433,333 shares of common stock to the same director upon conversion of his convertible notes payable of $13,000 at $0.03 per share.

On May 9, 2021 the Company issued 3,000,000 shares of common stock to a principal of GTI Corporate Transfer Agents, LLC of which an officer of the Company owns 50%. The Company recorded an expense of $180,000 based on the closing stock quote on the date of issuance.

Note 5 – Accrued expenses

The Company’s accrued expenses consisted of the following:

	June 30, 2022		December 31, 2021
Accrued officer salaries (see below)	$	6,191,623	$	5,958,623
Accrued interest		95,646		94,534
Other		1,233,303		1,233,494
Accrued expenses	$	7,520,572	$	7,286,651

Table of Contents

Note 6 – Convertible notes payable

The Company received $13,000 in proceeds from a director of the Company in exchange for convertible notes during the six months ended June 30, 2022. The notes were converted to 433,000 shares of common stock during this same period at $0.03 per share resulting in a zero balance as of June 30, 2022.

The Company’s issued convertible notes are due on demand, bearing interest at an annual rate of 8%. The notes are convertible into shares of Company common stock at a conversion price of $0.01 to $0.05 per share. As of June 30, 2022 and December 31, 2021, the total outstanding principal and interest is $54,500.

As of June 30, 2021, an analysis of the principal amount of convertible notes payable that have elected conversion to common stock amounted to $366,000. The Company’s transfer agent has been constrained in its efforts to issue the common stock for these convertible notes due to the noncompliance of the Company’s filing requirements. The Company has ceased accruing interest on these convertible notes but continues to accrue interest on the remaining convertible notes of $54,500. The convertible notes that have elected conversion without the stock being issued have been included in ‘Accrued liabilities’ on the Balance Sheet.

Note 7 – Shareholders’ equity

Preferred Stock

The Company has authorized 20,000,000 shares of Series A Preferred Stock, $0.001 par value, and 30,000,000 shares of Series B Preferred Stock, $0.001 par value.

As of June 30, 2022 and December 31, 2021, the Company had 0 shares Series A Preferred Stock issued and outstanding respectively.

As of June 30, 2022 and December 31, 2021, the Company had 26,038,572 shares of Series B Preferred Stock issued and outstanding respectively.

Common stock

The Company has authorized 300,000,000 shares of its common stock, $0.001 par value. The Company had issued and outstanding 35,333,319 and 34,083,319 shares of common stock as of June 30, 2022 and December 31, 2021, respectively.

During the three months ended June 30, 2022, the Company issued 816,667 shares of common stock to a new director of the Company for services and recognized a stock based consulting expense of $24,500. During the same period, the Company issued 433,333 shares of common stock to this director upon conversion of his convertible notes payable of $13,000 at $0.03 per share.

On March 18, 2021, the Company issued 1,500,000 restricted common shares to Venus Capital Fund, LLC for consulting services related to security and capital raise efforts. The Company recorded a consulting expense of $55,500.

On May 9, 2021 the Company issued 3,000,000 restricted shares of common stock to a principal of GTI Corporate Transfer Agents, LLC of which an officer of the Company owns 50%. The Company recorded an expense of $180,000 based on the closing stock quote on the date of issuance.

Table of Contents

Note 8 – Commitments

Employment Agreements

In 2022, the Company renewed the five-year employment agreements with its chief executive and scientific officer and its chief administrative and financial officer. The agreements provide for compensation of $21,500 and $17,333 per month, respectively, and expires on January 31, 2025.

Office Space Lease

The Company has a temporary office space at 3051 W 105^th Ave. #350251, in Westminster, CO as of June 30, 2021. The lease term does not warrant the establishment of a right of use asset or liability. No asset or liability has been recorded on the balance sheet.

The impact of COVID-19 on the Company is unknown at this time. The financial consequences of this situation cause uncertainty as to the future and its effects on the economy and the Company.

The Russian-Ukraine conflict is a global concern. The Company does not have any direct exposure to Russia or Ukraine through its operations, employee base, investments or sanctions. We have no basis to evaluate the possible risks of this conflict.

Note 9 – Subsequent events

On July 9, 2022 the Company entered into a convertible note payable with a director of the Company for $5,000 bearing interest at 8% per annum and convertible at $0.03 per share.

Table of Contents

ITEM 2: MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

CAUTOINARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Sections of this Form 10-Q, including the Management’s Discussion and Analysis or Plan of Operation, contain “forward-looking statements”. These forward-looking statements are subject to risks and uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statements. You should not unduly rely on these statements. Forward-looking statements involve assumptions and describe our plans, strategies, and expectations. You can generally identify a forward-looking statement by words such as “may,” “will,” “should,” “would,” “could,” “plans,” “goal,” “potential,” “expect,” “anticipate,” “estimate,” “believe,” “intent,” “project,” and similar words and variations thereof. This report contains forward-looking statements that address, among other things,

*	Our financing plans

*	Regulatory environments in which we operate or plan to operate

*	Trends affecting our financial condition or results of operations

*	The impact of competition, the start-up of certain operations and acquisition opportunities.

Factors, risks, and uncertainties that could cause actual results to differ materially from those in the forward-looking statements (“Cautionary Statements”) include, among others,

*	Our ability to raise capital

*	Our ability to execute our business strategy in a very competitive environment

*	Our degree of financial leverage

*	Risks associated with our acquiring and integrating companies into our own

*	Risks relating to rapidly developing technology

*	Regulatory considerations

*	Risks related to international economies

*	Risks related to market acceptance and demand for our products and services

*	The impact of competitive services and pricing

*	Other risks referenced from time to time in our SEC filings

All subsequent written and oral forward-looking statements attributable to us, or anyone acting on our behalf, are expressly qualified in their entirety by the cautionary statements. We do not undertake any obligations to publicly release any revisions to any forward-looking statements to reflect events or circumstances after the date of this report or to reflect unanticipated events that may occur.

You should read the following discussion of our results and plan of operation in conjunction with the consolidated financial statements and the notes thereto appearing elsewhere in this Form 10-Q. Statements in this Management’s Discussion and Analysis or Plan of Operation that are not statements of historical or current objective fact are “forward-looking statements.”

OVERVIEW

We have developed proprietary diagnostic assays for use in the COVID-19 together with agricultural and veterinary markets. Specific assays for COVID-19; Chronic Wasting Disease (CWD) (among elk and deer) and Mad Cow Disease (among cattle) have been developed and are available currently on a limited basis. E. coli (predominantly cattle) and Johne’s disease (predominantly cattle and bison) diagnostics are in development. We are also working on vaccine solutions to meet the growing demands of today’s veterinary industry and tomorrow’s agriculture and healthcare industries. The Company is organized and operated both to continually apply its scientific research to more effective management of diseases and, in so doing, realize the commercial potential of molecular biotechnology.

Table of Contents

Our business model is based on the development of a proprietary Molecular Robotic/AI Laboratory Platform (“MORAP”), which would combine the use of advanced robotic laboratory systems integrated with AI software systems on a global scale. Upon development, MORAP would encompass a nationwide network of interactive molecular laboratories operated using advanced integrated robotic and machine learning cloud-based software systems, which would be able to share data and interact with each other. We believe MORAP would be capable of processing millions of samples and collecting, storing and analyzing data. We believe that MORAP nationwide communications network could be accomplished through advanced cloud-based software systems, machine learning and Internet-of-Things (IoT) networks. Upon development, MORAP could be readily replicated and scaled utilizing identical instrumentation and software.

We have not generated significant operating revenue as of June 30, 2022. Our ability to generate substantial operating revenue will depend on our ability to develop and obtain approval for molecular assays and developing therapeutic vaccines for the detection and prevention of food contaminating pathogens, veterinary diseases, and diseases affecting human health.

Our independent auditors have expressed substantial doubt about our ability to continue as a going concern in their report on our consolidated financial statements as of December 31, 2021. For the six months ended June 30, 2022 and 2021, our net losses were $280,683 and $492,613, respectively. Our current liabilities exceeded current assets by $8,418,512 and $8,177,968 as of June 30, 2022 and December 31, 2021, respectively.

We will require significant additional funding in order to achieve our business plan. Over the next 12 months, in order to have the capability of achieving our business plan, we believe that we will require at least $40,000,000 in additional funding. We will attempt to raise these funds by both means of one or more private offerings of debt or equity securities. In such events, we may need immediate additional funding. Our capital requirements will depend on many factors including, but not limited to, the timing of further development of assays to detect the presence of infectious disease from the blood of live animals, our hiring of additional personnel, the applications for, and receipt of, regulatory approvals for any veterinary vaccines that we may develop, and other factors. Our ability to raise capital will increase our ability to implement our business plan.

We also expect to spend a significant amount of our capital on research and development activities for commercialization relating to development and vaccine design/development. When we are able to develop assays for different diseases, we intend to formalize the procedure into a commercial application through a series of laboratories to be owned and operated by GeneThera. To date, we have introduced our diagnostic solution for Chronic Wasting Disease (CWD) and Mad Cow Disease on a very limited basis. We anticipate that significant funds will be spent on research and development throughout the life of the Company, as this is the source for new products to be introduced to the market. Our plan is to seek new innovations in the robotic biotechnology field. We may be successful in developing or validating any new assays and, when we are successful in developing and validating any such assays, we may be able to successfully commercialize them or earn profits from sales of those assays. Furthermore, we may be able to design, develop, or successfully commercialize vaccines as a result of our research and development efforts.

RELATED PARTY TRANSACTIONS

RECENTLY ISSUED ACCOUNTING STANDARDS

Management has evaluated all recent accounting pronouncements as issued by the FASB in the form of Accounting Standards Updates (“ASU”) through the date these financial statements were available to be issued and find no recent accounting pronouncements that would have a material impact on the financial statements of the Company.

Table of Contents

EMPLOYEES

As of June 30, 2022, we had a total of two full-time employees who devoted substantial effort on our behalf. None of our employees are represented by a collective bargaining unit. We entered into an employment agreement with Antonio Milici, M.D., Ph.D., to serve as our Chief Executive Officer and Chief Scientific Officer through January 31, 2025. In consideration for his services, Dr. Milici will receive a base salary of $258,000 per annum plus bonuses as may be determined by the Board of Directors at its sole discretion. As part of his employment agreement, Dr. Milici is subject to non-disclosure and non-competition obligations and has transferred to the Company all of his interests in any idea, concept, technique, invention or written work. We also entered into an employment agreement with Tannya L. Irizarry to serve as our Chief Administrative Officer through January 31, 2025. Since May 2006, Ms. Irizarry is also our Chief Financial Officer (Interim). Ms. Irizarry’s base salary is $208,000 per annum. There are no employee issues at this time.

RESULTS OF OPERATIONS

FOR THE THREE MONTHS ENDED JUNE 30, 2022 and 2021

The company did not generate any revenue for the three months ended June 30, 2022 and 2021.

The company had total operating expenses of $147,382 and $284,726 for the three months ended June 30, 2022 and 2021, respectively, a decrease of $137,344 from the prior period due in part to the recognition of stock-based compensation categorized as consulting fees during the three months ended June 30, 2021.

We had a net loss of $ 147,938 and $492,613 for the three months ended June 30, 2022 and 2021, respectively, resulting in a decrease of $138,434 from the prior period due to the recognition of stock-based compensation categorized as consulting fees in the prior period.

FOR THE SIX MONTHS ENDED JUNE 30, 2022 and 2021

The company has not generated any revenue for the six months ended June 30, 2022 and 2021.

The company had total operating expenses of $279,571 and $489,321 for the six months ended June 30, 2022 and 2021, respectively, a decrease of $209,750 due to the recognition of stock-based expenses categorized as consulting fees in 2021.

We had a net loss of $ 280,683 and $492,613 for the six months ended June 30, 2022 and 2021, respectively, a decrease of $211,930 from the prior period due to the recognition of stock-based expenses categorized as consulting fees.

LIQUIDITY AND CAPITAL RESOURCES

As of June 30, 2022, we had cash and cash equivalents of $0. We have historically financed activities with cash from the private placement of equity and debt securities and advances from related parties. Our auditors have issued a going concern opinion. This means that our auditors believe there is a substantial doubt that we can continue as an on-going business for the next twelve months unless we obtain additional capital to pay our bills. We have had negligible revenues since inception and had an accumulated deficit of $32,552,129 and negative working capital of $8,418,512 as of June 30, 2022.

Our current cash balance is not sufficient to fund our business objectives and we will need significant additional capital over the next 12-18 months in order to fund our planned operations. Specifically, we intend to spend significant funds on completing our robotic prototype system, validating and testing our products, seeking necessary regulatory approvals and focusing on international expansion. We will attempt to raise capital through one or more private offerings of debt or equity securities or both. We may not be able to secure the financing that we believe is necessary to implement our strategic objectives and, even if additional financing is secured, we may not achieve our strategic objectives. As of the date of this report, we do not have any firm commitments from any investors for any additional funding.

Our longer-term working capital and capital requirements will depend upon numerous factors, including revenue and profit generation, pre-clinical studies and clinical trials, the timing and cost of obtaining regulatory approvals, the cost of filing, prosecuting, defending, and enforcing patent claims and other intellectual property rights, competing technological and market developments, collaborative arrangements. Additional capital will be required in order to attain such goals. Such additional funds may not become available on acceptable terms, and we cannot give assurance that any additional funding that we do obtain will be sufficient to meet our needs in the long term.

The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on recoverability and classification of liabilities that may result from the outcome of this uncertainty. If we are unable to obtain additional working capital, our business may fail. Accordingly, we must raise cash from sources other than operations. To date, we have financed our operations primarily through cash flow from limited operations, augmented by cash proceeds from financing activities, short-term borrowings and equity contributions by our stockholders. We must raise cash to implement our projected plan of operations. Failure to obtain capital to fund short-term and long-term needs will likely result in the curtailment of our operations or cessation of certain aspects of our business strategy.

The Company has no off-balance sheet commitments or arrangements.

Table of Contents

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Pursuant to Item 305(e) of Regulation S-K (§ 229.305(e)), the Company is not required to provide the information required by this Item as it is a “smaller reporting company,” as defined by Rule 229.10(f)(1).

Item 4. Controls and Procedures.

(a) Evaluation of Disclosure Controls and Procedures

Pursuant to Rule 13a-15(b) under the Exchange Act, the Company carried out an evaluation, with the participation of the Company’s management, including the Company’s Principal Executive Officer (“PEO”) and Principal Financial Officer (“PFO”), of the effectiveness of the Company’s disclosure controls and procedures (as defined under Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, the Company’s PEO and PFO concluded that the Company’s disclosure controls and procedures were not effective to ensure that information required to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including the Company’s PEO and PFO, as appropriate, to allow timely decisions regarding required disclosure

(b) Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

The Company is committed to improving financial organization. As part of this commitment, management and the Board perform reviews of the Company’s policies and procedures as they relate to financial reporting in an effort to mitigate future risks of potential misstatements. The Company will continue to focus on developing and documenting internal controls and procedures surrounding the financial reporting process, primarily through the use of account reconciliations, and supervision.

Table of Contents

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The Company believes that there are no current lawsuits or litigation.

Item 1A. Risk Factors

There have been no material changes from the risk factors previously disclosed in the Company’s Annual Report on Form 10-K, filed with the Commission on April 14, 2022 and investors are encouraged to review such risk factors prior to making an investment in the Company.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The Company issued 433,333 restricted shares of common stock when convertible notes of $13,000 were converted at $0.03 per share, and issued 816,667 restricted shares of common stock to a new director of the Company for services at $0.03 per share.

Item 3. Defaults upon Senior Securities

None.

Item 4: Mine Safety Disclosures

Not applicable.

Item 5: Other Information

There is no other information required to be disclosed under this item which has not been previously disclosed.

Table of Contents

Item 6: Exhibits

Exhibit Number		Description of Exhibit
31.1*		Certificate of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2*		Certificate of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1*		Certification by the Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2*		Certification by the Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS*		Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document)

101.SCH*		Inline XBRL Taxonomy Extension Schema Document

101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB*		Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

_____________

*	Filed herewith.

Table of Contents

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on August 17, 2022.

GeneThera, Inc.

By:	/s/ Antonio Milici
	Antonio Milici, M.D., Ph.D.
	President
	(Principal Executive Officer)

By:	/s/ Tannya L. Irizarry
	Tannya L. Irizarry
	Chief Financial Officer (Interim)
	(Principal Financial/Accounting Officer)

In accordance with the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

Signature	Title	Date

/s/ Antonio Milici	President, Director	08/17/2022
Antonio Milici, M.D., PhD.

/s/ Tannya L. Irizarry	Chief Financial Officer (Interim)	08/17/2022
Tannya L Irizarry

GENETHERA INC 10-Q